1. At a Glance
In a sector where one FDA alert can decimate sentiment, Aarti Drugs has walked a tightrope of regulatory drama, solar diversification, and flat sales. Now, with FY26 underway and import alerts lifted, can this pharma veteran deliver growth beyond its existing API catalog?
2. Introduction with Hook
Imagine being the student who aced every exam for 10 years… and then suddenly stopped topping the class. That’s Aarti Drugs. Once a momentum darling of API bulls, it’s now trading at a 3.5x book value with no firecracker revenue growth to back it.
- Q1 FY26 Net Profit: ₹54 Cr (+63% YoY, but off a low base)
- FY25 Revenue: ₹2,387 Cr (down from ₹2,529 Cr in FY24)
- Stock Performance: Just 2% CAGR over 1 year despite business recovery signs
3. Business Model (WTF Do They Even Do?)
Aarti Drugs is no rookie. Founded in 1984 and part of the $1B Aarti Group, it’s one of India’s oldest API manufacturers. Here’s the playbook:
- Core Segments:
- Active Pharmaceutical Ingredients (APIs)
- Pharma Intermediates
- Formulations
- Specialty Chemicals
- Global Footprint:
- Exports to 100+ countries
- Leading global producer of:
- Fluoroquinolones
- Tinidazole, Metronidazole Benzoate
- Nimesulide, Ketoconazole
- Among top Metformin producers worldwide
